<i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges
High frequencies of <i>MYD88<sup>L265P</sup></i> mutation are observed in IgM monoclonal gammopathies, and specifically in Waldenström macroglobulinemia (WM), indicating this mutation as a potential disease biomarker. Given the fact that <i>MYD88<sup>L265P</sup...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Hemato |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6357/4/3/21 |
| _version_ | 1797579803830779904 |
|---|---|
| author | Tina Bagratuni Alexandra Papadimou Kostantina Taouxi Meletios A. Dimopoulos Efstathios Kastritis |
| author_facet | Tina Bagratuni Alexandra Papadimou Kostantina Taouxi Meletios A. Dimopoulos Efstathios Kastritis |
| author_sort | Tina Bagratuni |
| collection | DOAJ |
| description | High frequencies of <i>MYD88<sup>L265P</sup></i> mutation are observed in IgM monoclonal gammopathies, and specifically in Waldenström macroglobulinemia (WM), indicating this mutation as a potential disease biomarker. Given the fact that <i>MYD88<sup>L265P</sup></i> mutation has been described as a key driver mutation, has increased our understanding of the biology behind MYD88 signaling and helped us to identify the functional components which could be targeted. On the other hand, the absence of the <i>MYD88<sup>L265P</sup></i> mutation in patients with IgM monoclonal gammopathies has been associated with a higher risk of transformation to aggressive lymphomas, resistance to several therapies, and shorter overall survival. The present review focuses on the molecular mechanisms that shape the signaling pattern in <i>MYD88<sup>WT</sup></i> cells, as well as on the clinical implications and therapeutic challenges of WM patients that harbor the <i>MYD88<sup>WT</sup></i> genotype. |
| first_indexed | 2024-03-10T22:42:06Z |
| format | Article |
| id | doaj.art-3af5bcbe59144a44954e45aa9c7bee54 |
| institution | Directory Open Access Journal |
| issn | 2673-6357 |
| language | English |
| last_indexed | 2024-03-10T22:42:06Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hemato |
| spelling | doaj.art-3af5bcbe59144a44954e45aa9c7bee542023-11-19T10:57:21ZengMDPI AGHemato2673-63572023-09-014325927210.3390/hemato4030021<i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical ChallengesTina Bagratuni0Alexandra Papadimou1Kostantina Taouxi2Meletios A. Dimopoulos3Efstathios Kastritis4Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, GreeceHigh frequencies of <i>MYD88<sup>L265P</sup></i> mutation are observed in IgM monoclonal gammopathies, and specifically in Waldenström macroglobulinemia (WM), indicating this mutation as a potential disease biomarker. Given the fact that <i>MYD88<sup>L265P</sup></i> mutation has been described as a key driver mutation, has increased our understanding of the biology behind MYD88 signaling and helped us to identify the functional components which could be targeted. On the other hand, the absence of the <i>MYD88<sup>L265P</sup></i> mutation in patients with IgM monoclonal gammopathies has been associated with a higher risk of transformation to aggressive lymphomas, resistance to several therapies, and shorter overall survival. The present review focuses on the molecular mechanisms that shape the signaling pattern in <i>MYD88<sup>WT</sup></i> cells, as well as on the clinical implications and therapeutic challenges of WM patients that harbor the <i>MYD88<sup>WT</sup></i> genotype.https://www.mdpi.com/2673-6357/4/3/21Waldenström macroglobulinemiaMYD88wild typeIgM monoclonal gammopathies |
| spellingShingle | Tina Bagratuni Alexandra Papadimou Kostantina Taouxi Meletios A. Dimopoulos Efstathios Kastritis <i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges Hemato Waldenström macroglobulinemia MYD88 wild type IgM monoclonal gammopathies |
| title | <i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges |
| title_full | <i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges |
| title_fullStr | <i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges |
| title_full_unstemmed | <i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges |
| title_short | <i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges |
| title_sort | i myd88 i wild type in igm monoclonal gammopathies from molecular mechanisms to clinical challenges |
| topic | Waldenström macroglobulinemia MYD88 wild type IgM monoclonal gammopathies |
| url | https://www.mdpi.com/2673-6357/4/3/21 |
| work_keys_str_mv | AT tinabagratuni imyd88iwildtypeinigmmonoclonalgammopathiesfrommolecularmechanismstoclinicalchallenges AT alexandrapapadimou imyd88iwildtypeinigmmonoclonalgammopathiesfrommolecularmechanismstoclinicalchallenges AT kostantinataouxi imyd88iwildtypeinigmmonoclonalgammopathiesfrommolecularmechanismstoclinicalchallenges AT meletiosadimopoulos imyd88iwildtypeinigmmonoclonalgammopathiesfrommolecularmechanismstoclinicalchallenges AT efstathioskastritis imyd88iwildtypeinigmmonoclonalgammopathiesfrommolecularmechanismstoclinicalchallenges |